Literature DB >> 21609224

Radiation treatment for age-related macular degeneration.

Ruwan A Silva1, Andrew A Moshfeghi, Peter K Kaiser, Rishi P Singh, Darius M Moshfeghi.   

Abstract

Age-related macular degeneration (AMD) remains a devastating cause of visual loss among elderly individuals. While considerable progress has been made towards combating the disease, most recently with intravitreal anti-VEGF agents, visual outcomes are still limited by continued retinal pigment epithelium (RPE) degeneration and subsequent neurosensory retinal atrophy. Among the promising new treatment options being explored, radiotherapy appears apt to address the multifactorial etiology of AMD. Current investigative studies underway will hopefully yield clinical efficacy to complement this theoretical suitability for arresting visual loss.

Entities:  

Mesh:

Year:  2011        PMID: 21609224     DOI: 10.3109/08820538.2011.554486

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  8 in total

1.  Enhancing RPE Cell-Based Therapy Outcomes for AMD: The Role of Bruch's Membrane.

Authors:  Janosch P Heller; Keith R Martin
Journal:  Transl Vis Sci Technol       Date:  2014-07-03       Impact factor: 3.283

Review 2.  Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review.

Authors:  Stephanie R Rice; Matthew S J Katz; Minesh P Mehta
Journal:  Int J Part Ther       Date:  2016-03-24

3.  Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD.

Authors:  Jay Chhablani; Rama Jager; Joshua Ong; Ryan Lohrenz; Russell J Hamilton; Baldassare Stea; Mary Drew; Gregg Kokame
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.117

4.  [Adjuvant stereotactic low energy radiation therapy of exudative age-dependent macular degeneration (Oraya system)].

Authors:  S Pollithy; N Celik; H Höh; S Dithmar
Journal:  Ophthalmologe       Date:  2013-05       Impact factor: 1.059

5.  Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo.

Authors:  Tao Li; Bogale Aredo; Kaiyan Zhang; Xin Zhong; Jose S Pulido; Shusheng Wang; Yu-Guang He; Xianming Huang; Rolf A Brekken; Rafael L Ufret-Vincenty
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

Review 6.  Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering.

Authors:  P Fernández-Robredo; A Sancho; S Johnen; S Recalde; N Gama; G Thumann; J Groll; A García-Layana
Journal:  J Ophthalmol       Date:  2014-01-14       Impact factor: 1.909

Review 7.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors:  Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal:  Br J Ophthalmol       Date:  2014-09       Impact factor: 4.638

Review 8.  Epimacular brachytherapy for wet AMD: current perspectives.

Authors:  Ricardo P Casaroli-Marano; Socorro Alforja; Joan Giralt; Michel E Farah
Journal:  Clin Ophthalmol       Date:  2014-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.